Already have an ACS ID? Log in
Renew your membership, and continue to enjoy these benefits.
Already an ACS Member? Log in here
Choose the membership that is right for you. Discounts will be applied automatically at checkout.
Enjoy these benefits no matter which membership you pick.
Most Popular in Business
Genentech will pay $120 million up front to partner with the antibody company Xencor on new cancer immunotherapies based on a protein called interleukin-15 (IL-15). Xencor’s lead program in the partnership combines IL-15 and its receptor, IL-15Rα, into a single protein designed to activate immune cells that can attack cancer. Xencor could receive up to $160 million more for developing the lead candidate and up to $180 million for each subsequent IL-15 drug.
This article has been sent to the following recipient: